

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Naoki Kimura <i>et al.</i>	
		Filing Date April 20, 2007	Group Art Unit 1643
(37 CFR §1.98(b))			

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/AMG/	1	5,747,654	05/05/1998	Pastan <i>et al.</i>			
/AMG/	2	5,892,020	04/06/1999	Mezcs <i>et al.</i>			
/AMG/	3	2007/0087381	04/19/2007	Kojima			
/AMG/	4	2008/0107654	05/08/2008	Kikuchi <i>et al.</i>			
/AMG/	5	2008/0286280	11/20/2008	Kallmeyer <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes No
/AMG/	6	AU 2002/210917	05/18/2006	Australia			X
/AMG/	7	AU 2004/297111	06/23/2005	Australia			X
/AMG/	8	EP 1 900 814	03/19/2008	Europe			
/AMG/	9	JP 10-510842	10/20/1998	Japan			Abstract only
/AMG/	10	WO 96/40218	12/19/1996	WIPO			
/AMG/	11	WO 01/036486	05/25/2001	WIPO			
/AMG/	12	WO 2008/071394	06/19/2008	WIPO			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/AMG/	13	CHOWDHURY <i>et al.</i> , "Engineering scFvs for improved stability," <i>Methods Mol. Biol.</i> , 207:237-54 (2003)
/AMG/	14	GenBank: U27005.1, <i>Mus musculus</i> , isolate 7183Liv, Vh183 lg heavy chain variable region gene, Vh region, partial cds, 1 page (April 1996)
/AMG/	15	GenBank: AY081858.1, <i>Mus musculus</i> , isolate H3-9 anti-GBM immunoglobulin kappa chain variable region mRNA, partial cds, 1 page (March 2004)
/AMG/	16	JUNG <i>et al.</i> , "The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains," <i>J. Mol. Biol.</i> , 309(3):701-16 (2001)
/AMG/	17	LOFFLER, "A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes," <i>Blood</i> , 95(6):2098-2103 (2000)
/AMG/	18	FISH & RICHARDSON, Amendment in Reply to Action dated April 23, 2010 in U.S. App. Ser. No. 10/530,696, filed October 22, 2010, 8 pages
/AMG/	19	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed January 7, 2011, 9 pages

Examiner Signature /Anne M. Gussow/	Date Considered /Anne M. Gussow/
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Naoki Kimura <i>et al.</i>	
		Filing Date April 20, 2007	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/AMG/	20	U.S. EXAMINER PENSEE T. DO, USPTO Final Office Action in U.S. App. Ser. No. 10/582,176, mailed October 29, 2010, 11 pages
/AMG/	21	FISH & RICHARDSON P.C., Amendment in Reply to Action dated October 29, 2010 in U.S. App. Ser. No. 10/582,176, filed April 28, 2011, 10 pages
/AMG/	22	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 16, 2010 in U.S. App. Ser. No. 10/582,413, filed October 15, 2010, 11 pages
/AMG/	23	U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser. No. 10/582,413, mailed December 23, 2010, 12 pages
/AMG/	24	FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement mailed May 3, 2010 in U.S. App. Ser. No. 11/910,117, filed November 2, 2010, 11 pages
/AMG/	25	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/910,117, mailed January 24, 2011, 10 pages
/AMG/	26	FISH & RICHARDSON P.C., Response to Restriction Requirement dated March 31, 2010 and Preliminary Amendment in U.S. App. Ser. No. 11/916,981, filed September 29, 2010, 6 pages
/AMG/	27	U.S. EXAMINER YUNSOO KIM, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/916,981, mailed December 3, 2010, 8 pages
/AMG/	28	FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement dated July 1, 2010 in U.S. App. Ser. No. 11/916,979 filed November 30, 2010, 9 pages
/AMG/	29	U.S. EXAMINER HONG SANG, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/916,979, mailed January 21, 2011, 15 pages
/AMG/	30	U.S. EXAMINER MEERA NATARAJAN, USPTO Restriction Requirement in U.S. App. Ser. No. 11/916,351, mailed September 3, 2010, 8 pages
/AMG/	31	FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement dated September 3, 2010 in U.S. App. Ser. No. 11/916,351, filed December 2, 2010, 9 pages
/AMG/	32	U.S. EXAMINER ANNE L. HOLLERAN, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/916,351, mailed March 3, 2011, 11 pages
/AMG/	33	U.S. EXAMINER YAN XIAO, USPTO Restriction Requirement in U.S. App. Ser. No. 12/530,670, mailed March 21, 2011, 7 pages

Examiner Signature /Anne M. Gussow/	Date Considered /Anne M. Gussow/
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	